title: Treatment of paediatric cerebral palsy with Dysport.
abstract: Dysport (Clostridium botulinum type A toxin-haemagglutin complex) has had its licence extended to include treatment of children aged 2 years and over with dynamic equinus foot deformity, caused by spasticity associated with cerebral palsy. Dysport reduces muscle tone, thus improving function, relieving pain, and facilitating physiotherapy, application and tolerability of splints.
authors: Molecular Medicine Unit, University of Leeds.
authors: T
authors: T
authors: Ubhi
mesh_terms: D000293:Adolescent; D018726:Anti-Dyskinesia Agents / Q000494:pharmacology*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D006388:Hemagglutinins / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009128:Muscle Spasticity / Q000188:drug therapy
chemical_list: D018726:Anti-Dyskinesia Agents; D004338:Drug Combinations; D006388:Hemagglutinins; D019274:Botulinum Toxins, Type A